NCT04087018 - Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

June 17, 2024

Study Completion Date

June 17, 2024

Conditions

Advanced Solid Tumors

Interventions

DRUG

zimberelimab

zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.

Trial Locations (9)

18103

Lehigh Valley Hospital, Allentown

19713

Christiana Care Health System - Helen F. Graham Cancer Center, Newark

20879

Kaiser Permanente Mid-Atlantic, Gaithersburg

29605

Prisma Health, Greenville

29607

Saint Francis Cancer Center, Greenville

54601

Gundersen Lutheran Medical Center, La Crosse

55416

Metro MN CCOP, Saint Louis Park

92120

Southern California Permanente Medical Group, Riverside

95661

Kaiser Permanente (NorCal) - Roseville, Roseville